Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib

Novartis Pharmaceuticals29 enrolled

Overview

Patients with metastatic renal cell carcinoma (mRCC) who failed first-line therapy with sunitinib or pazopanib was treated with everolimus. Efficacy and safety of everolimus was evaluated in these patients.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Metastatic Renal Cell Carcinoma (mRCC)

Interventions

Everolimus (RAD001)DRUG

Everolimus was used as commercially available formulated tablets of 10 mg strength

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with advanced renal cell carcinoma of a histological or cytological confirmation of clear cell renal carcinoma. * Progression during or after a treatment with sunitinib or pazopanib given in a 1st line treatment situation for mRCC. * Patients scheduled for treatment with everolimus. * Patients with at least one measurable lesion at baseline as per RECIST v1.1. Exclusion Criteria: * Patients who have received \>1 prior systemic treatment for their metastatic RCC. Prior systemic treatment in an adjuvant setting is allowed. * Patients who have previously received systemic mTOR inhibitors (e.g. sirolimus, temsirolimus, everolimus). * Patients who are using other investigational agents or who had received investigational drugs ≤ 2 weeks prior to study treatment start. * Patients unwilling or unable to comply with the protocol.

Locations (13)

Novartis Investigative Site

Chemnitz, Germany

Novartis Investigative Site

Dresden, Germany

Novartis Investigative Site

Hanover, Germany

Outcomes

Primary Outcomes

Percentage of Progression-free Patients by Month 6

Percentage of progression-free patients by month 6 after starting everolimus treatment. For the purpose of the binomial design of the study, a patient being 'progression-free' will be defined as a patient without disease progression by month 6 whereas a subject with progressive disease by month 6 will not be counted as 'progression-free'. The primary variable was derived from radiologic tumor assessments according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.) Disease progression was either 1) a 20% increase in the sum of the longest diameter of all target lesions, taking as reference the smallest sum of the longest diameters of all target lesions recorded at or after baseline (minimum absolute increase 5 mm in sum) or 2) the appearance of a new lesion or 3) the unequivocal progression of non-target lesions overall.

Time frame: Month 6

Secondary Outcomes

Percentage of Patients With Overall Response Rate (ORR) Treated With Everolimus After Failure of First-line Sunitinib or Pazopanib Therapy at Month 6

Overall response rate (ORR) is the Percentage of patients with a best overall response of complete response (CR) or partial response (PR) by month 6. ORR was assessed according to RECIST 1.1 criteria. Partial response (PR) required at least a 30% decrease in the sum of the longest diameters of all target lesions, taking as reference the baseline sum of the longest diameters. Complete response (CR) required a disappearance of all target and non-target lesions.

Time frame: Month 6

Progression-Free Survival (PFS) as the Time Interval Between First Intake of Everolimus and First Documented Disease Progression or Death Due to Any Cause at 24 Months

Progression-free survival (PFS) is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient did not have an event, progression-free survival was censored at the date of last adequate tumor assessment

Time frame: 24 months

Overall Survival (OS) of Patients Treated With Everolimus After Failure of First-line Sunitinib or Pazopanib Therapy up to 48 Months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.